查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1971888

CRISPR技术市场分析及预测（至2035年）：按类型、产品类型、服务、技术、应用、最终用户、组件、部署类型、解决方案和发展阶段划分

CRISPR Technology Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Component, Deployment, Solutions, Stage
出版日期: | 出版商: Global Insight Services | 英文 343 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计CRISPR技术市场规模将从2024年的36.254亿美元成长到2034年的86.523亿美元，复合年增长率约为15.8%。 CRISPR技术市场涵盖基因编辑工具和解决方案，利用CRISPR-Cas9系统精确修改DNA。该市场横跨生物技术、农业和製药等领域，推动基因研究、作物改良和治疗方法开发的发展。对个人化医疗和农业永续性发展日益增长的需求正在推动市场成长，并促进以递送方式、脱靶效应和监管合规性为重点的创新。

受基因工程进步和研究应用拓展的推动，CRISPR技术市场正经历强劲成长。其中，治疗领域成长最为显着，这主要得益于基因编辑疗法在治疗遗传疾病的潜力。肿瘤学应用前景特别广阔，可望为多种癌症提供新的治疗方法。农业领域也紧随其后，这主要受改良作物性状和增强抗虫害能力的需求所驱动。为了满足永续农业实践的需求，植物基因组编辑技术正受到广泛关注。诊断领域也正在崛起，成为另一个高成长领域，基于CRISPR的诊断工具能够快速、精准地检测疾病。这一增长主要由感染疾病日益普遍以及对快速诊断解决方案的需求所驱动。对CRISPR技术的投资也不断增加，製药和生物技术公司处于行业前沿，推动创新和市场发展。

市场区隔
类型 基因组编辑、基因工程、基于CRISPR的治疗方法、基于CRISPR的诊断
产品 CRISPR试剂盒、CRISPR文库、CRISPR试剂、CRISPR质体、CRISPR酶
服务 基因编辑服务、细胞株设计、CRISPR筛检服务、咨询服务
科技 CRISPR/Cas9、CRISPR/Cas12a、CRISPR/Cas13、基础编辑、主编辑
应用领域 生物医学研究、农业研究、药物研发、临床应用、诊断
最终用户 生技公司、製药公司、学术和研究机构、受託研究机构
成分 引导RNA，供体DNA模板
部署 体内、体外、试管内
解决方案 客製化 CRISPR 解决方案，即用型解决方案
步 药物发现研究阶段、临床前阶段、临床阶段、商业化阶段

市场概况：

随着主要企业透过策略性产品推出不断拓展产品组合，CRISPR技术市场正经历市场份额的动态变化。各公司正在调整定价策略，以平衡产品的可及性和创新性。市场的一个显着特征是新参与企业数量的快速成长，每个新进业者都试图利用CRISPR的变革潜力。现有企业则专注于提升产品的精准度和效率，以在竞争中脱颖而出。基因编辑技术在农业、医疗保健和生物技术等各个领域的应用进展，推动了这个蓬勃发展的市场的形成。 CRISPR技术市场的竞争异常激烈，主要企业竞相争取技术优势。基准分析表明，那些在研发方面投入巨资的公司正在製定行业标准。监管的影响在北美和欧洲等地区尤其显着，这些地区严格的指导方针塑造着市场动态。这些法规旨在确保伦理考量，并影响产品开发週期。此外，学术机构和商业组织之间的合作也对市场产生影响，并促进创新。这些伙伴关係对于克服监管挑战和加速市场准入至关重要，使 CRISPR 技术市场成为科学和商业性活动的中心。

主要趋势和驱动因素：

受基因编辑技术在各领域应用进展的推动，CRISPR技术市场正经历强劲成长。一个关键趋势是CRISPR技术在农业领域的应用日益广泛，透过提高作物产量和增强抗虫害能力，有助于应对粮食安全挑战。在医疗保健领域，CRISPR正在革新个人化医疗，为遗传性疾病和罕见疾病提供潜在治疗方法。药厂正在利用CRISPR技术进行药物发现与开发，加速创新治疗方法的研发进程。基于CRISPR的诊断工具的兴起是另一个新兴趋势，能够快速且准确地检测感染疾病。政府和私部门的监管支持和资金投入是研发活动的关键驱动力。伦理考量和社会接受度正在塑造市场动态，并影响法规结构和投资决策。随着CRISPR技术的不断发展，投资研发和拓展其应用的公司将迎来盈利的机会。

限制与挑战：

CRISPR技术市场面临许多重大限制与挑战。其中一项主要挑战是围绕基因编辑的伦理问题，这引发了公众的焦虑和监管机构的审查。这场道德辩论可能会延缓核准流程，并限制市场扩张。此外，CRISPR技术潜在的脱靶效应也带来了科学难题。这些非预期的基因修饰可能产生不可预测的后果，因此需要进一步的研究和开发来提高其准确性和安全性。 CRISPR技术的高成本也是一大障碍，使其主要面向资金雄厚的机构和公司。这一经济门槛限制了其在各领域的广泛应用。知识产权纠纷也是一项重大挑战。复杂的专利情况可能导致法律纠纷，并阻碍产业内的创新与合作。最后，精通CRISPR技术的专业人员短缺。这种技能缺口阻碍了CRISPR解决方案在各个领域的有效应用和发展。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 基因组编辑
    • 基因工程
    • 基于CRISPR的疗法
    • 基于CRISPR的诊断
  • 市场规模及预测：依产品划分
    • CRISPR试剂盒
    • CRISPR文库
    • CRISPR试剂
    • CRISPR质体
    • CRISPR酶
  • 市场规模及预测：依服务划分
    • 基因编辑服务
    • 细胞株工程
    • CRISPR筛检服务
    • 咨询服务
  • 市场规模及预测：依技术划分
    • CRISPR/Cas9
    • CRISPR/Cas12a
    • CRISPR/Cas13
    • 基础编辑
    • Prime Edit
  • 市场规模及预测：依应用领域划分
    • 生物医学研究
    • 农业调查
    • 药物研发
    • 临床应用
    • 诊断
  • 市场规模及预测：依最终用户划分
    • 生技公司
    • 製药公司
    • 学术和研究机构
    • 合约研究机构
  • 市场规模及预测：依组件划分
    • 引导RNA
    • 供体DNA模板
  • 市场规模及预测：依发展状况
    • In vivo
    • Ex Vivo
    • 体外
  • 市场规模及预测：按解决方案划分
    • 客製化 CRISPR 解决方案
    • 即用型解决方案
  • 市场规模及预测：依发展阶段划分
    • 发现
    • 临床前阶段
    • 临床
    • 商业的

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • CRISPR Therapeutics
  • Editas Medicine
  • Intellia Therapeutics
  • Caribou Biosciences
  • Beam Therapeutics
  • Mammoth Biosciences
  • Synthego
  • Cellectis
  • Precision Biosciences
  • eGenesis
  • Ergomed
  • Locus Biosciences
  • Inscripta
  • Metagenomi
  • Pairwise

第九章：关于我们

简介目录
Product Code: GIS33752

CRISPR Technology Market is anticipated to expand from $3,625.4 million in 2024 to $8,652.3 million by 2034, growing at a CAGR of approximately 15.8%. The CRISPR Technology Market encompasses tools and solutions for gene editing, utilizing CRISPR-Cas9 systems to modify DNA with precision. This market spans sectors such as biotechnology, agriculture, and pharmaceuticals, driving advancements in genetic research, crop enhancement, and therapeutic development. The increasing demand for personalized medicine and agricultural sustainability fuels growth, with innovations focusing on delivery methods, off-target effects, and regulatory compliance.

The CRISPR Technology Market is experiencing robust growth, driven by advancements in genetic engineering and increasing research applications. The therapeutics segment is the top-performing area, with gene editing therapies leading the charge due to their potential to treat genetic disorders. Within this segment, oncology applications are particularly promising, offering novel treatment avenues for various cancers. The agriculture segment follows closely, driven by the need for improved crop traits and pest resistance. Plant genome editing is gaining significant traction, reflecting the demand for sustainable agricultural practices. Diagnostics is emerging as a secondary high-performing segment, with CRISPR-based diagnostic tools offering rapid and precise disease detection capabilities. This growth is fueled by the rising prevalence of infectious diseases and the need for quick diagnostic solutions. Investment in CRISPR technology is also expanding, with pharmaceutical and biotech companies at the forefront, fostering innovation and driving market evolution.

Market Segmentation
TypeGenome Editing, Genetic Engineering, CRISPR-based Therapeutics, CRISPR-based Diagnostics
ProductCRISPR Kits, CRISPR Libraries, CRISPR Reagents, CRISPR Plasmids, CRISPR Enzymes
ServicesGene Editing Services, Cell Line Engineering, CRISPR Screening Services, Consulting Services
TechnologyCRISPR/Cas9, CRISPR/Cas12a, CRISPR/Cas13, Base Editing, Prime Editing
ApplicationBiomedical Research, Agricultural Research, Drug Development, Clinical Applications, Diagnostics
End UserBiotechnology Companies, Pharmaceutical Companies, Academic & Research Institutes, Contract Research Organizations
ComponentGuide RNA, Donor DNA Templates
DeploymentIn Vivo, Ex Vivo, In Vitro
SolutionsCustom CRISPR Solutions, Ready-to-use Solutions
StageDiscovery, Preclinical, Clinical, Commercial

Market Snapshot:

The CRISPR Technology Market is witnessing a dynamic shift in market share, with key players expanding their portfolios through strategic product launches. Pricing strategies are evolving as companies seek to balance accessibility with innovation. The landscape is characterized by a surge in new entrants, each aiming to capitalize on the transformative potential of CRISPR. Established firms are focusing on enhancing the precision and efficiency of their offerings, driving competitive differentiation. This vibrant market is fueled by advancements in gene editing applications across various sectors, including agriculture, healthcare, and biotechnology. Competition in the CRISPR Technology Market is intense, with leading companies vying for technological supremacy. Benchmarking reveals that firms investing heavily in R&D are setting industry standards. Regulatory influences are significant, particularly in regions like North America and Europe, where stringent guidelines shape market dynamics. These regulations ensure ethical considerations are met, impacting product development timelines. The market is further influenced by collaborations between academic institutions and commercial entities, fostering innovation. Such partnerships are pivotal in overcoming regulatory challenges and accelerating market entry, making the CRISPR Technology Market a hub of scientific and commercial activity.

Geographical Overview:

The CRISPR technology market is experiencing robust growth across various regions, each showcasing unique potential. North America remains at the forefront, driven by substantial investments in biotechnology and a strong focus on genetic research. The presence of leading biotech firms and research institutions further accelerates market development. Europe is not far behind, with significant government support and funding initiatives fostering innovation in gene editing. The region's regulatory landscape, which emphasizes ethical considerations, also contributes to a balanced growth environment. In the Asia Pacific, the market is rapidly expanding, underpinned by increasing research activities and collaborations between academic and commercial entities. Countries like China and Japan are emerging as key players due to their strong focus on technological advancement. Latin America and the Middle East & Africa are witnessing nascent growth stages, with rising awareness and investments in genetic research. These regions are recognizing CRISPR's potential to address healthcare challenges and drive scientific progress.

Key Trends and Drivers:

The CRISPR Technology Market is experiencing robust growth, driven by advancements in gene-editing applications across various sectors. A key trend is the increasing utilization of CRISPR in agriculture, where it enhances crop yield and resistance to pests, thereby addressing food security challenges. In the healthcare sector, CRISPR is revolutionizing personalized medicine, offering potential cures for genetic disorders and rare diseases. Pharmaceutical companies are leveraging CRISPR for drug discovery and development, accelerating the pace of creating innovative treatments. The rise of CRISPR-based diagnostic tools is another trend, providing rapid and accurate detection of infectious diseases. Regulatory support and funding from governments and private sectors are significant drivers, facilitating research and development activities. Ethical considerations and public acceptance are shaping market dynamics, influencing regulatory frameworks and investment decisions. As CRISPR technology continues to evolve, it presents lucrative opportunities for companies investing in research and expanding their application portfolios.

Restraints and Challenges:

The CRISPR Technology Market faces several significant restraints and challenges. One primary challenge is the ethical concerns surrounding gene editing, which raise public apprehension and regulatory scrutiny. This moral debate can slow down the approval process and limit market expansion. Additionally, the potential off-target effects of CRISPR technology pose a scientific challenge. These unintended genetic modifications can lead to unpredictable outcomes, necessitating further research and development to enhance precision and safety. The high cost of CRISPR technology is another barrier, restricting access primarily to well-funded institutions and companies. This financial hurdle limits widespread adoption and application in diverse fields. Intellectual property disputes also present a significant challenge. Complicated patent landscapes can lead to legal battles, stifling innovation and collaboration within the industry. Lastly, there is a lack of skilled professionals proficient in CRISPR technology. This skills gap hampers the efficient implementation and advancement of CRISPR-based solutions across various sectors.

Key Players:

CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Caribou Biosciences, Beam Therapeutics, Mammoth Biosciences, Synthego, Cellectis, Precision Biosciences, eGenesis, Ergomed, Locus Biosciences, Inscripta, Metagenomi, Pairwise

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Component
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Solutions
  • 2.10 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Genome Editing
    • 4.1.2 Genetic Engineering
    • 4.1.3 CRISPR-based Therapeutics
    • 4.1.4 CRISPR-based Diagnostics
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 CRISPR Kits
    • 4.2.2 CRISPR Libraries
    • 4.2.3 CRISPR Reagents
    • 4.2.4 CRISPR Plasmids
    • 4.2.5 CRISPR Enzymes
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Gene Editing Services
    • 4.3.2 Cell Line Engineering
    • 4.3.3 CRISPR Screening Services
    • 4.3.4 Consulting Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 CRISPR/Cas9
    • 4.4.2 CRISPR/Cas12a
    • 4.4.3 CRISPR/Cas13
    • 4.4.4 Base Editing
    • 4.4.5 Prime Editing
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Biomedical Research
    • 4.5.2 Agricultural Research
    • 4.5.3 Drug Development
    • 4.5.4 Clinical Applications
    • 4.5.5 Diagnostics
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Biotechnology Companies
    • 4.6.2 Pharmaceutical Companies
    • 4.6.3 Academic & Research Institutes
    • 4.6.4 Contract Research Organizations
  • 4.7 Market Size & Forecast by Component (2020-2035)
    • 4.7.1 Guide RNA
    • 4.7.2 Donor DNA Templates
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 In Vivo
    • 4.8.2 Ex Vivo
    • 4.8.3 In Vitro
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Custom CRISPR Solutions
    • 4.9.2 Ready-to-use Solutions
  • 4.10 Market Size & Forecast by Stage (2020-2035)
    • 4.10.1 Discovery
    • 4.10.2 Preclinical
    • 4.10.3 Clinical
    • 4.10.4 Commercial

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Component
      • 5.2.1.8 Deployment
      • 5.2.1.9 Solutions
      • 5.2.1.10 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Component
      • 5.2.2.8 Deployment
      • 5.2.2.9 Solutions
      • 5.2.2.10 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Component
      • 5.2.3.8 Deployment
      • 5.2.3.9 Solutions
      • 5.2.3.10 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Component
      • 5.3.1.8 Deployment
      • 5.3.1.9 Solutions
      • 5.3.1.10 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Component
      • 5.3.2.8 Deployment
      • 5.3.2.9 Solutions
      • 5.3.2.10 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Component
      • 5.3.3.8 Deployment
      • 5.3.3.9 Solutions
      • 5.3.3.10 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Component
      • 5.4.1.8 Deployment
      • 5.4.1.9 Solutions
      • 5.4.1.10 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Component
      • 5.4.2.8 Deployment
      • 5.4.2.9 Solutions
      • 5.4.2.10 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Component
      • 5.4.3.8 Deployment
      • 5.4.3.9 Solutions
      • 5.4.3.10 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Component
      • 5.4.4.8 Deployment
      • 5.4.4.9 Solutions
      • 5.4.4.10 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Component
      • 5.4.5.8 Deployment
      • 5.4.5.9 Solutions
      • 5.4.5.10 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Component
      • 5.4.6.8 Deployment
      • 5.4.6.9 Solutions
      • 5.4.6.10 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Component
      • 5.4.7.8 Deployment
      • 5.4.7.9 Solutions
      • 5.4.7.10 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Component
      • 5.5.1.8 Deployment
      • 5.5.1.9 Solutions
      • 5.5.1.10 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Component
      • 5.5.2.8 Deployment
      • 5.5.2.9 Solutions
      • 5.5.2.10 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Component
      • 5.5.3.8 Deployment
      • 5.5.3.9 Solutions
      • 5.5.3.10 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Component
      • 5.5.4.8 Deployment
      • 5.5.4.9 Solutions
      • 5.5.4.10 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Component
      • 5.5.5.8 Deployment
      • 5.5.5.9 Solutions
      • 5.5.5.10 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Component
      • 5.5.6.8 Deployment
      • 5.5.6.9 Solutions
      • 5.5.6.10 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Component
      • 5.6.1.8 Deployment
      • 5.6.1.9 Solutions
      • 5.6.1.10 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Component
      • 5.6.2.8 Deployment
      • 5.6.2.9 Solutions
      • 5.6.2.10 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Component
      • 5.6.3.8 Deployment
      • 5.6.3.9 Solutions
      • 5.6.3.10 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Component
      • 5.6.4.8 Deployment
      • 5.6.4.9 Solutions
      • 5.6.4.10 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Component
      • 5.6.5.8 Deployment
      • 5.6.5.9 Solutions
      • 5.6.5.10 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 CRISPR Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Editas Medicine
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Intellia Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Caribou Biosciences
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Beam Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Mammoth Biosciences
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Synthego
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Cellectis
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Precision Biosciences
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 eGenesis
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Ergomed
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Locus Biosciences
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Inscripta
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Metagenomi
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Pairwise
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us